Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PH-797804 in moderate to severe COPD
NCT01543919Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2012
- Primary completion
- Sep 2013
- Modality
- Classical Binding Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of PH-797804 in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Pfizer. Primary endpoint: Forced Expiratory Volume in 1 second at 12 weeks. Started Apr 2012; status: completed.
02
Drugs
PH-797804
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01543919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01543919.